The Centers for Disease Control and Prevention (CDC), Agency for Toxic Substances and Disease Registry (ATSDR) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639-7570 or send an email to firstname.lastname@example.org. Send written comments to ATSDR Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written comments should be received within 30 days of this notice.
National Amyotrophic Lateral Sclerosis (ALS) Registry—Revision (0923-0041, Expiration 7/31/13)—Agency for Toxic Substances and Disease Registry (ATSDR).
Background and Brief Description
On October 10, 2008, President Bush signed S. 1382: ALS Registry Act which amended the Public Health Service Act to provide for the establishment of an Amyotrophic Lateral Sclerosis (ALS) Registry. The activities described are part of the effort to create the National ALS Registry. The purpose of the registry is to: (1) Better describe the incidence and prevalence of ALS in the United States; (2) examine appropriate Start Printed Page 26781factors, such as environmental and occupational, that might be associated with the disease; (3) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (4) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS. The registry will collect personal health information that may provide a basis for further scientific studies of potentially risks for developing ALS.
After piloting methodology, on October 18, 2010 the Agency for Toxic Substances and Disease Registry (ATSDR) launched the registration component of the National ALS Registry.
The registration portion of the data collection will be limited to information that can be used to identify an individual to assure that there are not duplicate records for an individual. Avoiding duplication of registrants due to obtaining records from multiple sources is imperative to get accurate estimates of incidence and prevalence, as well as accurate information on demographic characteristics of the cases of ALS.
In addition to questions required for registration, there will be a series of short surveys to collect information on such things as military history, occupations, residential history, and family history that would not likely be available from other sources.
This project proposes to add 10 additional risk factor surveys while continuing to collect information on individuals with ALS which can be combined with information obtained from existing sources of information. This combined data will become the National ALS Registry and will be used to provide more accurate estimates of the incidence and prevalence of disease as well as the demographic characteristics of the cases. Information obtained from the surveys will be used to better characterize potential risk factors for ALS which will lead to further in-depth studies.
The existence of the Web site (http://wwwn.cdc.gov/als) is being advertised by ATSDR and advocacy groups such as the Amyotrophic Lateral Sclerosis Association (ALSA) and the Muscular Dystrophy Association (MDA). There are no costs to the respondents other than their time. The estimated annualized burden hours are 1,375.
Estimated Annualized Burden Hours
|Type of respondent||Form name||Number of respondents||Number of responses per respondent||Average burden per
|Person with ALS||Validation questions (Screener) for suspected ALS cases||1,670||1||2/60|
| ||Registration Form of ALS cases||1,500||1||7/60|
| ||Cases of ALS completing 1-time surveys||750||16||5/60|
| ||Cases of ALS completing twice yearly surveys||750||2.3||5/60|
Ron A. Otten,
Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.
[FR Doc. 2013-10853 Filed 5-7-13; 8:45 am]
BILLING CODE 4163-18-P